4,298 Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Bought by First Heartland Consultants Inc.

First Heartland Consultants Inc. purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 4,298 shares of the medical equipment provider's stock, valued at approximately $454,000.

Other large investors have also recently bought and sold shares of the company. PharVision Advisers LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at about $209,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Zimmer Biomet by 8.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,767,901 shares of the medical equipment provider's stock valued at $186,743,000 after buying an additional 140,531 shares during the period. Woodline Partners LP boosted its holdings in shares of Zimmer Biomet by 5.0% during the 4th quarter. Woodline Partners LP now owns 962,907 shares of the medical equipment provider's stock worth $101,712,000 after buying an additional 45,980 shares in the last quarter. Vivaldi Capital Management LP acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $7,657,000. Finally, Two Sigma Investments LP bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at $4,085,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Royal Bank of Canada cut their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. JMP Securities cut their price objective on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a research report on Wednesday, May 7th. Wells Fargo & Company decreased their target price on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Finally, Raymond James reduced their price objective on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet presently has a consensus rating of "Hold" and an average price target of $111.53.

Zimmer Biomet Stock Down 2.7%

ZBH opened at $92.73 on Thursday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.92 and a fifty-two week high of $120.13. The firm has a market capitalization of $18.35 billion, a P/E ratio of 20.84, a PEG ratio of 1.95 and a beta of 0.78. The company's 50-day moving average is $102.65 and its 200 day moving average is $105.59. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The firm had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The company's quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.94 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were given a $0.24 dividend. The ex-dividend date was Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 1.04%. Zimmer Biomet's dividend payout ratio is currently 21.24%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. The trade was a 14.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.39% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.